Document is current
Any future updates will be listed below
-
Authors
Watts, Justin
Nong, Tiffany
Micin, Katarina
Soong, Deborah
Madarang, Ellen
Affer, Maurizio
Mehra, Shefali
Lesmes, Jessica Alvarez
Chapman, Jennifer
Zhou, Yi
Thomassen, Amber
Bradley, Terrence
Totiger, Tulasigeri
Swords, Ronan
Taylor, Justin
-
Funding
Funding for this research was provided by:
National Cancer Institute (K08CA230319, P30CA240139)
Edward P. Evans Foundation (DRG)
Doris Duke Charitable Foundation (CSDA)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 16 June 2025
First Online: 1 July 2025
Competing interests
: J.W.: advisory board/consultancy: Servier, Rigel, BMS, Aptose, Daiichi Sankyo, Ativarre. Research support: Takeda, Rigel, Immune Systems Key, Ltd. A.T. is now an employee at Rigel Pharmaceuticals, Inc. T.T.: advisory board/consultancy: Morphosys, Novartis. Advisory: Sobi, Servier. DSMB: Karyopharm. R.S.: consultancy: Rigel, Abbvie. T.N., K.M., D.S., E.M., M.A., S.M., J.A.L., J.C., Y.Z., T.B., J.T.: Nothing to disclose.
